Source comparison
Tesamorelin + Ipamorelin Blend Stacking Guide: Protocol Comparison
The table below compares standard monotherapy protocols against the synergistic blend stacking approach, highlighting differences in dosing frequency, injection timing, and expected GH response patterns. Tesamorelin Monotherapy 1–2mg Before bed Increases pulse
This comparison does not assign a generated winner or score.
- The table below compares standard monotherapy protocols against the synergistic blend stacking approach, highlighting differences in dosing frequency, injection timing, and expected GH response patterns.
- Tesamorelin Monotherapy
- 1–2mg
- Before bed
- Increases pulse amplitude; no frequency change
- Low (GHRH receptors resistant to desensitization)
- Effective for amplitude-driven GH elevation but limited by natural pulse frequency. Total AUC constrained
- Ipamorelin Monotherapy
- 200–300mcg
- 2–3× daily
- Increases pulse frequency; minimal amplitude change
- Moderate to high if dosed >2× daily continuously
- Effective for frequency-driven GH elevation but receptor downregulation limits long-term efficacy without cycling
- Tesamorelin + Ipamorelin Blend (1mg + 1mg)
- 1mg + 1mg
- Once daily before bed
- Increases both amplitude and frequency synergistically
- Low (single daily dose prevents ghrelin receptor desensitization)
- Optimal for sustained GH elevation. Dual-pathway stimulation produces 3–5× higher AUC than monotherapy with minimal desensitization
- High-Dose Blend (2mg + 2mg)
- 2mg + 2mg
- Further amplitude increase; frequency benefit plateaus
- Moderate (higher Ipamorelin dose accelerates receptor downregulation)
- Reserve for research models with demonstrated tolerance. Provides marginal AUC benefit but increases desensitization risk
- The single daily injection protocol minimizes receptor desensitization while maximizing synergy. Splitting the blend into multiple daily injections. A common mistake. Increases ghrelin receptor activation frequency beyond the threshold that triggers downregulation, negating Ipamorelin's frequency-boosting effect within 2–3 weeks.